Search

Your search keyword '"Lunghi, F."' showing total 278 results

Search Constraints

Start Over You searched for: Author "Lunghi, F." Remove constraint Author: "Lunghi, F."
278 results on '"Lunghi, F."'

Search Results

1. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

5. P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY

6. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

7. Determinants of early triage for hospitalization in MPN patients with COVID-19

8. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

9. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

11. T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWED BY ADD-BACKS OF SUICIDE-GENE MODIFIED DONOR T-CELLS OFFERS LONG TERM SURVIVAL FREE OF IMMUNE SUPPRESSION TREATMENT: A 7 YEARS FOLLOW-UP IN 56 PATIENTS: PH-O084

14. Treosulfan-based conditioning regimen allows an early full donor chimerism after related and unrelated transplant with low toxicity. Results from a prospective single-centre study: P972

20. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

26. Risk factors for secondary cancer in a case-control study on 1,881 patients with myeloproliferative neoplasms (ELN Study)

27. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

28. PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

29. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis

30. Secondary solid tumors after allogeneic stem cell transplantation: active surveillance in long term follow-up

31. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY

32. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

33. Observational Study of CML Italian Patients Who Discontinued TKIs

34. Standardized care of long-term survivors after allogeneic stem cell transplantation: a cross-sectional 1-year evaluation in 249 adults

35. Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation

36. TRACKING T CELL DYNAMICS IN THE FIRST MONTH AFTER ALLOGENEIC HSCT OFFERS A UNIQUE OPPORTUNITY TO UNVEIL THE MECHANISM OF MEMORY STEM T CELL FORMATION IN HUMANS

37. Cardiovascular events and intensity of treatment in polycythemia vera

38. Comparative evaluation of the predictive power of the EBMT risk score and the Hematopoietic Cell Transplantation Co-morbidity Index for allogeneic haematopoietic stem cell transplantation in a treosulfan-based conditioning setting

40. Quantitative real-time PCR evaluation of Wilms tumour gene transcript levels in autologous peripheral blood stem cell can predict the risk of acute myeloid leukaemia relapse after autologous transplantation

41. Treosulfan-based conditioning regimen for allo-SCT in 283 patients: co-morbidity index and disease status are predictors of outcomes

42. Allogeneic transplantation in elderly patients with poor prognosis acute myeloid leukaemia or myelodysplastic syndrome; the San Raffaele Institute experience

43. Anidulafungin primary prophylaxis in 28 high-risk patients undergoing allogeneic haematopoietic stem cell transplantation: a single-centre experience

44. Implementation of an alternative donor is a prerequisite for a good intention-to-treat performance in patients in need of allogeneic transplantation: analysis of 361 patients

45. Timing and rate of success in transplant of matched unrelated donor (MUD) searches through bone marrow donors worldwide (BMDW): the case of San Raffaele Institute in 2006-2009

46. Monitoring of Willms' tumour gene 1 transcripts in AML and MDS patients can predict early relapse after allogeneic haematopoietic stem cell transplantation

48. ORAL VALGANCICLOVIR AS EARLY PRE-EMPTIVE TREATMENT FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE IN 45 PATIENTS

49. SECOND ALLOGENEIC STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT IN RELAPSED HAEMATOLOGICAL MALIGNANCIES: FEASIBILITY AND OUTCOME IN 26 PATIENTS

Catalog

Books, media, physical & digital resources